Evidence map›Paper›PMID 34842360›Full record

ArticlePediatric pulmonology2022

Surfactant protein D is a biomarker of influenza-related pediatric lung injury.

Arindam Chakrabarti, Allen Nguyen, Margaret M Newhams, Maikke B Ohlson, Xiaoying Yang, Sheila Ulufatu, Shannon Liu, Summer Park, Min Xu, Jenny Jiang and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Pathobiology, Severity, and Risk Stratification of Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Arindam ChakrabartiBiomarker Discovery, Genentech, Inc., South San Francisco, California, USA.
Allen NguyenBiomarker Development, Genentech, Inc., South San Francisco, California, USA.
Margaret M NewhamsDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Maikke B OhlsonBiomarker Discovery, Genentech, Inc., South San Francisco, California, USA.
Xiaoying YangBiostatistics, Genentech, Inc., South San Francisco, California, USA.
Sheila UlufatuDepartment of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.
Shannon LiuDepartment of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.
Summer ParkTranslational Immunology, Genentech, Inc., South San Francisco, California, USA.
Min XuTranslational Immunology, Genentech, Inc., South San Francisco, California, USA.
Jenny JiangBiomarker Development, Genentech, Inc., South San Francisco, California, USA.
Wendy G HalpernDepartment of Pathology, Genentech, Inc., South San Francisco, California, USA.
Veronica G AnaniaBiomarker Development, Genentech, Inc., South San Francisco, California, USA.
Jacqueline M McBrideBiomarker Development, Genentech, Inc., South San Francisco, California, USA.
Carrie M RosenbergerBiomarker Discovery, Genentech, Inc., South San Francisco, California, USA.
Adrienne G RandolphDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8189-8822
Pediatric Intensive Care Influenza (PICFLU) Investigators
Biomarker Technologies (China) · CNDiscovery Centre · CABoston Children's Hospital · USBiostatistical Consulting (United States) · USKaiser Permanente South San Francisco Medical Center · USPublic Knowledge · US

Funding

Immunobiology of Influenza Virus-related Critical Illness in Young HostsR01AI154470 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI RANDOLPH, ADRIENNE G, THOMAS, PAUL G. · 2020 to 2024
$4.7M
Genetic Epidemiology of Life-Threatening Influenza in ChildrenR01AI084011 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI RANDOLPH, ADRIENNE G · 2010 to 2013
$3.1M
Genetic Epidemiology of Life-Threatening Influenza Infection in ChildrenR56AI084011 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI RANDOLPH, ADRIENNE G · 2009 to 2009
$712k
NIAID NIH HHS R01 AI084011NIAID NIH HHS R01 AI154470NIAID NIH HHS R56 AI084011
6 · The paper itself

Abstract

backgroundBiomarkers that can risk-stratify children with influenza virus lower respiratory infection may identify patients for targeted intervention. Early elevation of alveolar-related proteins in the bloodstream in these patients could indicate more severe lung damage portending worse outcomes.

methodsWe used a mouse model of human influenza infection and evaluated relationships between lung pathophysiology and surfactant protein D (SP-D), SP-A, and Club cell protein 16 (CC16). We then measured SP-A, SP-D, and CC16 levels in plasma samples from 94 children with influenza-associated acute respiratory failure (PICFLU cohort), excluding children with underlying conditions explaining disease severity. We tested for associations between levels of circulating proteins and disease severity including the diagnosis of acute respiratory distress syndrome (ARDS), mechanical ventilator, intensive care unit and hospital days, and hospital mortality.

resultsCirculating SP-D showed a greater increase than SP-A and CC16 in mice with increased alveolar-vascular permeability following influenza infection. In the PICFLU cohort, SP-D was associated with moderate-severe ARDS diagnosis (p = 0.01) and with mechanical ventilator (r = 0.45, p = 0.002), ICU (r = 0.44, p = 0.002), and hospital days (r = 0.37, p = 0.001) in influenza-infected children without bacterial coinfection. Levels of SP-D were lower in children with secondary bacterial pneumonia (p = 0.01) and not associated with outcomes. CC16 and SP-A levels did not differ with bacterial coinfection and were not consistently associated with severe outcomes.

conclusionsSP-D has potential as an early circulating biomarker reflecting a degree of lung damage caused directly by influenza virus infection in children. Secondary bacterial pneumonia alters SP-D biomarker performance.

Indexed as

Influenza, HumanLung InjuryRespiratory Distress SyndromeAnimalsBiomarkersChildHumansMicePulmonary Surfactant-Associated Protein DBiomarkersPulmonary Surfactant-Associated Protein DARDSinfluenza virusmurinepediatricsurfactant proteins

Identifiers

PMID34842360
PMCPMC8792225
OpenAlexW3215425756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.